FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322416212> ?p ?o ?g. }

• W2322416212 endingPage "464" @default.
• W2322416212 startingPage "459" @default.
• W2322416212 abstract "HER2 is a target for antibody-based treatment of breast and gastric carcinoma which is highly successful in advanced disease as well as in the adjuvant setting. To determine the potential applicability of such therapies, salivary gland tumours were analysed for HER2 overexpression/amplification in this study.A tissue microarray (TMA) was constructed from 994 carcinomas and 205 adenomas of the salivary gland. Slides were analysed for HER2 overexpression and gene amplification using FDA approved reagents for immunohistochemistry (IHC; Hercep-Test; Dako) and fluorescence in situ hybridisation (FISH; PathVysion; Vysis-Abbott).HER2 was found overexpressed in 39 of 915 (4.26%) and amplified in nine of 915 interpretable salivary gland carcinomas (0.98%). HER2 overexpression was mostly found in salivary duct carcinoma. All other entities were mainly HER2 negative. HER2 was overexpressed in 34 of 319 (10.65%) mucoepidermoid carcinomas, one of 170 (0.59%) acinic cell adenocarcinomas and three of 14 (21.43%) salivary duct carcinomas. HER2 amplification was seen in three of 294 (1.01%) mucoepidermoid carcinomas, three of 14 (21.43%) salivary duct carcinomas, one of 81 (1.23%) adenocarcinomas (NOS), one of 12 (8.33%) cystadenocarcinomas and one of 19 (2.08%) myoepithelial carcinomas. HER2 amplification was found in seven of 39 immunohistochemically HER2 positive (2+ and 3+) tumours (17.95%) but in only two of 849 (0.24%) IHC negative tumours (p < 0.0001). No amplification/overexpression was found in adenoid cystic carcinoma, epithelial-myoepithelial carcinoma, polymorphous low grade carcinoma, basal cell carcinoma, myoepithelial carcinoma, cystadenocarcinoma and oncocytic carcinoma.HER2 overexpression caused by gene amplification was observed in about 20% of patients with salivary duct cancers but was rare in salivary adenomas and other carcinomas. Therefore, anti-HER2 therapy may represent a therapeutic option only in a small subgroup of salivary gland tumours." @default.
• W2322416212 created "2016-06-24" @default.
• W2322416212 creator A5021421424 @default.
• W2322416212 creator A5026822326 @default.
• W2322416212 creator A5040795485 @default.
• W2322416212 creator A5043553126 @default.
• W2322416212 creator A5053793365 @default.
• W2322416212 creator A5068158443 @default.
• W2322416212 creator A5072001228 @default.
• W2322416212 creator A5078383767 @default.
• W2322416212 creator A5079411842 @default.
• W2322416212 creator A5079884607 @default.
• W2322416212 date "2011-08-01" @default.
• W2322416212 modified "2023-09-26" @default.
• W2322416212 title "Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas" @default.
• W2322416212 cites W1536926326 @default.
• W2322416212 cites W1966202828 @default.
• W2322416212 cites W1966467322 @default.
• W2322416212 cites W1968436167 @default.
• W2322416212 cites W1969015681 @default.
• W2322416212 cites W1977794117 @default.
• W2322416212 cites W1977891261 @default.
• W2322416212 cites W1989796158 @default.
• W2322416212 cites W2009276029 @default.
• W2322416212 cites W2017984483 @default.
• W2322416212 cites W2035980465 @default.
• W2322416212 cites W2039633811 @default.
• W2322416212 cites W2042661015 @default.
• W2322416212 cites W2050307563 @default.
• W2322416212 cites W2052015772 @default.
• W2322416212 cites W2057572869 @default.
• W2322416212 cites W2068446510 @default.
• W2322416212 cites W2072103945 @default.
• W2322416212 cites W2082497313 @default.
• W2322416212 cites W2087436801 @default.
• W2322416212 cites W2098532770 @default.
• W2322416212 cites W2099823824 @default.
• W2322416212 cites W2101430012 @default.
• W2322416212 cites W2105023567 @default.
• W2322416212 cites W2112621891 @default.
• W2322416212 cites W2116951908 @default.
• W2322416212 cites W2126191879 @default.
• W2322416212 cites W2138523273 @default.
• W2322416212 cites W2139144874 @default.
• W2322416212 cites W2141393790 @default.
• W2322416212 cites W2146384083 @default.
• W2322416212 cites W2146442501 @default.
• W2322416212 cites W2155005773 @default.
• W2322416212 cites W2155320512 @default.
• W2322416212 cites W2156654723 @default.
• W2322416212 cites W2163947995 @default.
• W2322416212 cites W3140520760 @default.
• W2322416212 doi "https://doi.org/10.1097/pat.0b013e3283484a60" @default.
• W2322416212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21670724" @default.
• W2322416212 hasPublicationYear "2011" @default.
• W2322416212 type Work @default.
• W2322416212 sameAs 2322416212 @default.
• W2322416212 citedByCount "72" @default.
• W2322416212 countsByYear W23224162122012 @default.
• W2322416212 countsByYear W23224162122013 @default.
• W2322416212 countsByYear W23224162122014 @default.
• W2322416212 countsByYear W23224162122015 @default.
• W2322416212 countsByYear W23224162122016 @default.
• W2322416212 countsByYear W23224162122017 @default.
• W2322416212 countsByYear W23224162122018 @default.
• W2322416212 countsByYear W23224162122019 @default.
• W2322416212 countsByYear W23224162122020 @default.
• W2322416212 countsByYear W23224162122021 @default.
• W2322416212 countsByYear W23224162122022 @default.
• W2322416212 countsByYear W23224162122023 @default.
• W2322416212 crossrefType "journal-article" @default.
• W2322416212 hasAuthorship W2322416212A5021421424 @default.
• W2322416212 hasAuthorship W2322416212A5026822326 @default.
• W2322416212 hasAuthorship W2322416212A5040795485 @default.
• W2322416212 hasAuthorship W2322416212A5043553126 @default.
• W2322416212 hasAuthorship W2322416212A5053793365 @default.
• W2322416212 hasAuthorship W2322416212A5068158443 @default.
• W2322416212 hasAuthorship W2322416212A5072001228 @default.
• W2322416212 hasAuthorship W2322416212A5078383767 @default.
• W2322416212 hasAuthorship W2322416212A5079411842 @default.
• W2322416212 hasAuthorship W2322416212A5079884607 @default.
• W2322416212 hasConcept C140884156 @default.
• W2322416212 hasConcept C142724271 @default.
• W2322416212 hasConcept C204232928 @default.
• W2322416212 hasConcept C2777546739 @default.
• W2322416212 hasConcept C2778937882 @default.
• W2322416212 hasConcept C2779231225 @default.
• W2322416212 hasConcept C2780329156 @default.
• W2322416212 hasConcept C2780859518 @default.
• W2322416212 hasConcept C2781066530 @default.
• W2322416212 hasConcept C71924100 @default.
• W2322416212 hasConcept C86803240 @default.
• W2322416212 hasConceptScore W2322416212C140884156 @default.
• W2322416212 hasConceptScore W2322416212C142724271 @default.
• W2322416212 hasConceptScore W2322416212C204232928 @default.
• W2322416212 hasConceptScore W2322416212C2777546739 @default.
• W2322416212 hasConceptScore W2322416212C2778937882 @default.
• W2322416212 hasConceptScore W2322416212C2779231225 @default.

• next